Clinical trials: Mesenchymal Stromal Cells
Osteoarthritis
Autologous Adipose-Derived Stromal Cells Delivered Intra-articularly in Patients With Osteoarthritis.
This will be an open-label, non-randomized, multi-center, patient sponsored study of Adipose-Derived Stromal Vascular Fraction (AD-SVF) implantation performed intra-articularly to affected joints.
- Trial name
- NCT01739504
- Testing
- Liposuction with Local Anesthesia, Intra articular infusion of AD-SVF
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Ageless Regenerative Institute
Peripheral Artery Disease, Peripheral Vascular Disease
Safety of Intramuscular Injection of Allogeneic PLX-PAD Cells for the Treatment of Critical Limb Ischemia
The The purpose of this study is to determine the safety of PLX-PAD single dose, Intra-muscular injection for the treatment of CLI patients.
- Conditions
- Peripheral Artery Disease, Peripheral Vascular Disease, Critical Limb Ischemia
- Trial name
- NCT00919958
- Testing
- PLX-PAD IM injection
- Where
- Germany
- Volunteers
- 15 people
- Sponsor
- Pluristem Ltd.
Pneumoconiosis
Human Umbilical Cord-Mesenchymal Stem Cells for Pneumoconiosis
The purpose of this study is to evaluate the safety and efficacy of human umbilical cord mesenchymal stem cell(hUC-MSC) for Pneumoconiosis.
- Trial name
- NCT02790762
- Testing
- Human umbilical cord mesenchymal stem cells
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Shenzhen Hornetcorn Bio-technology Company, LTD
Life Threatening Diseases
Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases
Exploratory study to examine the effect(s) of Imatinib mesylate treatment on life threatening rare diseases with known associations to one or more Imatinib mesylate -sensitive tyrosine kinases, and to identify the contribution of…
- Trial name
- NCT00154388
- Testing
- Imatinib mesylate
- Volunteers
- 185 people
- Sponsor
- Novartis Pharmaceuticals
Liver Cirrhosis
Human Umbilical Cord Mesenchymal Stem Cells Transplantation for Patients With Decompensated Liver Cirrhosis
Although liver transplantation provide a option to cure patients suffering with decompensated liver cirrhosis this condition, lack of donors, postoperative complications, especially rejection, and high cost limit its application.
- Trial name
- NCT01342250
- Testing
- conventional therapy plus low dose hUC-MSCs treatment, conventional therapy plus medium dose hUC-MSCs treatment, conventional therapy plus high dose hUC-MSCs treatment
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shenzhen Beike Bio-Technology Co., Ltd.
Osteoarthritis,Knee
Treatment of Knee Osteoarthritis With Autologous Mesenchymal Stromal Cell Product (RegStem)
Osteoarthritis (OA) is a common and incurable disease for the elderly in Taiwan, so it is an important mission to develop a new treatment for OA.
- Trial name
- NCT03007576
- Testing
- RegStem
- Where
- Taiwan
- Volunteers
- 12 people
- Sponsor
- EMO Biomedicine Corporation
Perianal Fistula Due to Crohn's Disease, Fistula in Ano
Safety of Allogeneic Human Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) to Treat Perianal Fistulas w/ Crohn's Disease
Objectives: Primary: To demonstrate the safety of allogeneic UC-MSCs administered by injection for complex perianal fistulas in patients with Crohn's disease Secondary: To determine the efficacy of a single/multiple allogeneic…
- Trial name
- NCT05039411
- Testing
- PF2020-CELL (UC-MSCs) - Allogeneic Human Umbilical Cord Mesenchymal Stem Cells
- Where
- Malaysia
- Volunteers
- 5 people
- Sponsor
- CryoCord Sdn Bhd
Amyotrophic Lateral Sclerosis
Autologous Cultured Mesenchymal Bone Marrow Stromal Cells Secreting Neurotrophic Factors (MSC-NTF), in ALS Patients.
The study will evaluate the safety, tolerability and therapeutic effects (preliminary efficacy) of injection of autologous cultured mesenchymal bone marrow stromal cells secreting neurotrophic factors (MSC-NTF), as a possible…
- Trial name
- NCT01051882
- Testing
- MSC-NTF cells transplantation (IM), MSC-NTF cells transplantation (IT)
- Where
- Israel
- Volunteers
- 12 people
- Sponsor
- Brainstorm-Cell Therapeutics
Bradykinesia
Evaluate Umbilical Cord-derived Allogeneic Mesenchymal Stem Cells for the Treatment of Bradykinesia
Investigate the safety and tolerability of umbilical cord-derived allogeneic mesenchymal stem cells to treat patients with Bradykinesia.
- Trial name
- NCT04385056
- Testing
- MSCTC-0010
- Where
- 3 sites in United States
- Volunteers
- 15 people
- Sponsor
- IMAC Holdings, Inc.
Hepatic Cirrhosis
Human Umbilical Cord-Mesenchymal Stem Cells for Hepatic Cirrhosis
The purpose of this study is to evaluate the safety and efficacy of human umbilical cord mesenchymal stem cell(hUC-MSC) for Hepatic Cirrhosis.
- Trial name
- NCT02652351
- Testing
- Human umbilical cord mesenchymal stem cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shenzhen Hornetcorn Bio-technology Company, LTD
Steroid-refractory Acute Graft-versus-host Disease
Treatment Of Steroid-Refractory Acute Graft-versus-host Disease With Mesenchymal Stromal Cells Versus Best Available Therapy
The primary purpose of this trial is to demonstrate the superiority of MC0518 compared to the first used best available therapy (BAT) with respect to overall response rate (ORR) at Day 28 and/or overall survival (OS) until Visit…
- Trial name
- IDUNN (NCT04629833)
- Testing
- MC0518, BAT
- Where
- 42 sites in France, Germany and 3 more
- Volunteers
- 210 people
- Sponsor
- medac GmbH
Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19)
Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19)
The objectives of this intermediate-size expanded access protocol are to assess the safety and efficacy of remestemcel-L in participants with MIS-C associated with COVID-19.
- Trial name
- NCT04456439
- Testing
- Remestemcel-L, Hydrocortisone, Diphenhydramine
- Sponsor
- Mesoblast International Sàrl
Acute Ischemic Stroke, AIS
A Phase I Trial of Umbilical Cord Mesenchymal Stromal Cells for Acute Ischemic Stroke
Study Methods: The trial consists of two phases, both including a placebo control. Phase Ia (single-dose, dose-escalation): Three dose groups (low, medium, high) are set.
- Trial name
- NCT07628933
- Testing
- Human Umbilical Cord Mesenchymal Stem Cells Injection
- Where
- China
- Volunteers
- 35 people
- Sponsor
- BOE Technology Group Co., Ltd.
Osteonecrosis of Femoral Head
The Study of Early Stage Osteonecrosis of Femoral Head With Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife®-ONFH)
The purposes of the study is to evaluate the safety and efficacy of human umbilical cord mesenchymal stem cells (hUC-MSC) in treating osteonecrosis of femoral head patients.
- Trial name
- NCT03180463
- Testing
- Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#), core decompression
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sclnow Biotechnology Co., Ltd.
Heart Failure
The Study of Heart Failure With Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife®-HF)
The purposes of the study is to evaluate the safety and efficacy of human umbilical cord mesenchymal stem cells (hUC-MSC) in treating heart failure patients
- Trial name
- NCT03180450
- Testing
- Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#), conventional treatment
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Sclnow Biotechnology Co., Ltd.
Knee Osteoarthritis
A Trial to Evaluate the Safety, Tolerability, and Efficacy of NCR100 Injection in the Treatment of Subjects With KOA
This clinical study is to investigate the safety and efficacy of NCR100 injection in subjects with knee osteoarthritis (KOA). It is a dose-escalating, open label study in adult KOA subjects.
- Trial name
- NCR100 (NCT06049342)
- Testing
- NCR100 injection
- Volunteers
- 12 people
- Sponsor
- Nuwacell Biotechnologies Co., Ltd.
Coronary Artery Bypass Grafting (CABG), Chronic Heart Failure
A Phase I/II Clinical Trial of Intramyocardial Injection of HucMSCs for the Treatment of Chronic Heart Failure
B2278 is a human umbilical cord mesenchymal stem cell (HucMSCs) injection derived from the umbilical cord. It has the advantages of stronger immune regulation, stronger expansion capacity, lower immunogenicity, and greater…
- Conditions
- Coronary Artery Bypass Grafting (CABG), Chronic Heart Failure, Chronic Ischemic Cardiomyopathy
- Trial name
- NCT07265349
- Testing
- Mesenchymal stem cells(HucMSCs), CABG
- Where
- 4 sites in China
- Volunteers
- 51 people
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd
Myelodysplastic Syndromes
Research for Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife®-MDS) in the Treatment of Myelodysplastic Syndrome (MDS)
The purposes of the study is to determine the safety and efficacy of human umbilical cord mesenchymal stem cells (hUC-MSC) in treating Myelodysplastic Syndrome patients.
- Trial name
- NCT03184935
- Testing
- Allogeneic umbilical cord mesenchymal stem cells, Decitabine
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Sclnow Biotechnology Co., Ltd.
Decompensated Liver Cirrhosis
Safety of Umbilical Cord Mesenchymal Stem Cells (UC-MSC) in Patients With Decompensated Hepatitis B Cirrhosis
The goal of this clinical trial is to evaluate the safety and tolerability of multiple doses of human umbilical cord mesenchymal stem cell injection in patients with decompensated hepatitis B cirrhosis, and to further explore the…
- Trial name
- NCT05948982
- Testing
- Human Umbilical Cord Mesenchymal Stem Cells
- Volunteers
- 18 people
- Sponsor
- Asia Cell Therapeutics (Shanghai) Co., Ltd.
Grade B aGVHD, Grade C aGVHD
A Prospective Study of Remestemcel-L, Ex-vivo Cultured Adult Human Mesenchymal Stromal Cells, for the Treatment of Pediatric Participants Who Have Failed to Respond to Steroid Treatment for Acute Graft-Versus-Host Disease (aGVHD)
The study plans to treat at least 60 pediatric participants, male and female, between the ages of 2 months and 17 years inclusive with aGVHD following allogeneic hematopoietic stem cell transplant (HSCT) that has failed to…
- Conditions
- Grade B aGVHD, Grade C aGVHD, Grade D aGVHD
- Trial name
- NCT02336230
- Testing
- remestemcel-L
- Where
- 20 sites in United States
- Volunteers
- 55 people
- Sponsor
- Mesoblast, Inc.